Madrigal Pharmaceuticals (MDGL) Other Operating Expenses (2016 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Other Operating Expenses for 4 consecutive years, with $40.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Other Operating Expenses rose 341.33% year-over-year to $40.0 million; the TTM figure through Jun 2026 stood at $109.4 million (up 1281.09% YoY), while the FY2025 annual figure was $56.1 million, up 800.82% from the prior year.
• Other Operating Expenses climbed to $40.0 million in Q2 2026 per MDGL's latest filing, from $26.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $40.0 million in Q2 2026 and bottomed at -$7.8 million in Q4 2024.
• Historically, Other Operating Expenses has averaged $13.1 million across 3 years, with a median of $9.1 million in 2025.
• Annual changes were most pronounced in 2025 — Other Operating Expenses surged 1325.31% — and 2026, when it surged 341.33%.
• Madrigal Pharmaceuticals' Other Operating Expenses stood at -$7.8 million in 2024, then jumped by 413.15% to $24.4 million in 2025, then jumped by 63.64% to $40.0 million in 2026.
• Business Quant data shows MDGL's Other Operating Expenses at $40.0 million in Q2 2026, $26.8 million in Q1 2026, and $24.4 million in Q4 2025.